Terry Day to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Terry Day has written about Xenograft Model Antitumor Assays.
Connection Strength
0.165
-
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. Clin Cancer Res. 2019 02 15; 25(4):1156-1164.
Score: 0.150
-
Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther. 2006 Jun; 317(3):1188-99.
Score: 0.016